Cancer News

The latest in diagnostics and treatment

As a practice dedicated to the constant exploration of effective treatment for cancer, VCI aims to be your source for news on the latest breakthroughs. Please keep this page as a bookmark and check back regularly. Because one of the most important aspects of fighting cancer is knowing all you can.

World Cancer News

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors (08/02/2018)

The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and other tissue areas. About Pheochromocytoma and Paraganglioma Pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system. When pheochromocytomas …

Continue reading "FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors"

What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer? (07/25/2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion of an initial 5 years of treatment. The optimal duration of endocrine (hormone) therapy beyond five years after initial AI adjuvant therapy for postmenopausal women with hormone …

Continue reading "What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer?"

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (07/23/2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. Data leading to the FDA approval was from a trial that included …

Continue reading "Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation"

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer (07/23/2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also approved Kisqali in combination with fulvestrant for the …

Continue reading "FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer"

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN (07/19/2018)

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and …

Continue reading "Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN"

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (07/17/2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Xtandi was previously approved for the treatment of patients with metastatic CRPC. About Prostate Cancer Prostate cancer is …

Continue reading "FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer"

Cyramza Improves Survival in Poor-Prognosis Liver Cancer (07/12/2018)

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset of patients with hepatocellular carcinoma (HCC) who have high levels of the plasma protein α-fetoprotein (AFP), which is associated …

Continue reading "Cyramza Improves Survival in Poor-Prognosis Liver Cancer"

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (07/10/2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis according to the results of a study published in the Journal of …

Continue reading "Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer"

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients (07/09/2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American …

Continue reading "Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients"

Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors (07/06/2018)

A “smart bomb” oncolytic adenovirus appears to induce dramatic responses with long-term survival in recurrent high-grade gliomas, according to the early results of a study published in The Journal of Clinical Oncology. Glioblastoma is the most common and aggressive form of primary brain cancer in adults. With standard therapy — surgery followed by chemoradiation and …

Continue reading "Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors"